Eli Lilly & Co. vs. Xeris Biopharma Holdings, Inc. Common Stock
LLY
Eli Lilly & Co.
$1164.89 +1.04%
VS XERSXeris Biopharma Holdings, Inc. Common Stock
$8.73 +6.52%
Eli Lilly & Co. (LLY) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| LLY | XERS | |
|---|---|---|
| Market Cap | $1.03 trillion | $1.50 billion |
| Revenue (TTM) | $79.67 billion | $33.38 million |
| Net Income (TTM) | $26.71 billion | $-83,783,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | XERS | |
|---|---|---|
| P/E Ratio | 39.10 | — |
| Price / Book | 30.33 | 75.17 |
| Price / Sales | 12.90 | 44.79 |
LLY leads on 2 of 2 valuation factors.
Profitability
| LLY | XERS | |
|---|---|---|
| Net Margin | 33.53% | -251.01% |
| Return on Equity | 78.84% | -421.27% |
LLY leads on 2 of 2 profitability factors.
Dividend
| LLY | XERS | |
|---|---|---|
| Dividend Yield | 0.59% | — |
| Payout Ratio | 23.23 | — |
LLY and XERS split the dividend factors evenly.
Risk & Sentiment
| LLY | XERS | |
|---|---|---|
| Short Interest | 1.29% | 0.10% |
XERS leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, XERS overview, XERS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.